A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
440 patients around the world
Available in Spain, Brazil, Argentina, United States
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
440Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
